BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 31139940)

  • 1. Multiplex PCR analysis of apocrine lesions shows frequent PI3K-AKT pathway mutations in both benign and malignant apocrine breast tumors.
    Kanomata N; Yamaguchi R; Kurebayashi J; Moriya T
    Med Mol Morphol; 2020 Mar; 53(1):15-20. PubMed ID: 31139940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutational Analysis of AKT1 and PIK3CA in Intraductal Papillomas of the Breast with Special Reference to Cellular Components.
    Mishima C; Kagara N; Ikeda JI; Morii E; Miyake T; Tanei T; Naoi Y; Shimoda M; Shimazu K; Kim SJ; Noguchi S
    Am J Pathol; 2018 May; 188(5):1106-1112. PubMed ID: 29454754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast.
    Troxell ML; Levine J; Beadling C; Warrick A; Dunlap J; Presnell A; Patterson J; Shukla A; Olson NR; Heinrich MC; Corless CL
    Mod Pathol; 2010 Jan; 23(1):27-37. PubMed ID: 19898424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Juvenile papillomatosis of the breast (Swiss cheese disease) has frequent associations with PIK3CA and/or AKT1 mutations.
    Guillet C; Rechsteiner M; Bellini E; Choschzick M; Moskovszky L; Dedes K; Papassotiropoulos B; Varga Z
    Hum Pathol; 2020 Apr; 98():64-73. PubMed ID: 32088208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sclerosing Polycystic Adenoma of Salivary Glands: A Novel Neoplasm Characterized by PI3K-AKT Pathway Alterations-New Insights Into a Challenging Entity.
    Skálová A; Baněčková M; Laco J; Di Palma S; Agaimy A; Ptáková N; Costes-Martineau V; Petersson BF; van den Hout MFCM; de Rezende G; Klubíčková N; Koblížek M; Koshyk O; Vaneček T; Leivo I
    Am J Surg Pathol; 2022 Feb; 46(2):268-280. PubMed ID: 34510113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and spectrum of AKT1, PIK3CA, PTEN and TP53 somatic mutations in Chinese breast cancer patients.
    Li G; Guo X; Chen M; Tang L; Jiang H; Day JX; Xie Y; Peng L; Xu X; Li J; Wang S; Xiao Z; Dai L; Wang J
    PLoS One; 2018; 13(9):e0203495. PubMed ID: 30212483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adenomyoepitheliomas of the Breast Frequently Harbor Recurrent Hotspot Mutations in PIK3-AKT Pathway-related Genes and a Subset Show Genetic Similarity to Salivary Gland Epithelial-Myoepithelial Carcinoma.
    Lubin D; Toorens E; Zhang PJ; Jaffer S; Baraban E; Bleiweiss IJ; Nayak A
    Am J Surg Pathol; 2019 Jul; 43(7):1005-1013. PubMed ID: 31094929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutation profiling in the PIK3CA, TP53, and CDKN2A genes in circulating free DNA and impalpable breast lesions.
    Delmonico L; Costa MASM; Fournier MV; Romano SO; Nascimento CMD; Barbosa AS; Moreira ADS; Scherrer LR; Ornellas MHF; Alves G
    Ann Diagn Pathol; 2019 Apr; 39():30-35. PubMed ID: 30634138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer.
    Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Tomiguchi M; Sueta A; Murakami K; Iwase H
    Mol Cancer; 2018 Feb; 17(1):67. PubMed ID: 29482551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PIK3CA-AKT pathway mutations in micropapillary breast carcinoma.
    Flatley E; Ang D; Warrick A; Beadling C; Corless CL; Troxell ML
    Hum Pathol; 2013 Jul; 44(7):1320-7. PubMed ID: 23352210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma.
    Dunlap J; Le C; Shukla A; Patterson J; Presnell A; Heinrich MC; Corless CL; Troxell ML
    Breast Cancer Res Treat; 2010 Apr; 120(2):409-18. PubMed ID: 19418217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphatidylinositol-3-kinase pathway mutations are common in breast columnar cell lesions.
    Troxell ML; Brunner AL; Neff T; Warrick A; Beadling C; Montgomery K; Zhu S; Corless CL; West RB
    Mod Pathol; 2012 Jul; 25(7):930-7. PubMed ID: 22460814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mucinous breast carcinomas lack PIK3CA and AKT1 mutations.
    Kehr EL; Jorns JM; Ang D; Warrick A; Neff T; Degnin M; Lewis R; Beadling C; Corless CL; Troxell ML
    Hum Pathol; 2012 Dec; 43(12):2207-12. PubMed ID: 22705004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
    Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H
    PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression.
    Kalinsky K; Heguy A; Bhanot UK; Patil S; Moynahan ME
    Breast Cancer Res Treat; 2011 Sep; 129(2):635-43. PubMed ID: 21617917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Several genotypes, one phenotype: PIK3CA/AKT1 mutation-negative hidradenoma papilliferum show genetic lesions in other components of the signalling network.
    Pfarr N; Allgäuer M; Steiger K; Weichert W; Schirmacher P; Noske A; Stenzinger A
    Pathology; 2019 Jun; 51(4):362-368. PubMed ID: 31010589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer.
    Agahozo MC; Sieuwerts AM; Doebar SC; Verhoef EI; Beaufort CM; Ruigrok-Ritstier K; de Weerd V; Sleddens HFBM; Dinjens WNM; Martens JWM; van Deurzen CHM
    Endocr Relat Cancer; 2019 May; 26(5):471-482. PubMed ID: 30844755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutation of genes of the PI3K/AKT pathway in breast cancer supports their potential importance as biomarker for breast cancer aggressiveness.
    Tserga A; Chatziandreou I; Michalopoulos NV; Patsouris E; Saetta AA
    Virchows Arch; 2016 Jul; 469(1):35-43. PubMed ID: 27059323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes.
    Kim JY; Lee E; Park K; Park WY; Jung HH; Ahn JS; Im YH; Park YH
    Oncotarget; 2017 Apr; 8(17):27997-28007. PubMed ID: 28427202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.